Earn CME for related activities: [ Ссылка ]
In this webcast from the 'First- and Second-Line Treatment Updates in CLL: The Role of Targeted Therapy' symposium during the 2019 Lymphoma & Myeloma conference in New York, Dr. Richard R. Furman discusses treatment options for patients who progress after BTK inhibitor therapy.
© 2019 Imedex, an HMP Company
